Ischemix, Inc. is a biopharmaceutical company based in Maynard, MA, dedicated to developing innovative cytoprotective compounds for the prevention and treatment of serious diseases and conditions. Their lead product candidate, CMX-2043, is currently in preclinical development for traumatic brain injury (TBI) and has shown promising results in controlled studies, demonstrating significant improvements in sensorimotor activity, cognition, memory, contusion volume, hyperactive behavior, and biochemical assays.
With its multi-modal activity and strong preclinical data, CMX-2043 is a new chemical entity that holds great potential for addressing the complex conditions of TBI. Ischemix has obtained multiple issued patents for the composition of matter and method of use of CMX-2043 worldwide, and they are also exploring its potential for other therapeutic indications.
Generated from the website